These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 34806071)

  • 1. Antithrombotic therapy in patients with liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding.
    Chang WH; Mueller SH; Tan YY; Lai AG
    Lancet Reg Health Eur; 2021 Nov; 10():100222. PubMed ID: 34806071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.
    Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Flaherty K; Duley L; England TJ; Havard D; Heptinstall S; James M; Kasonde C; Krishnan K; Markus HS; Montgomery AA; Pocock S; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N
    Health Technol Assess; 2018 Aug; 22(48):1-76. PubMed ID: 30179153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
    Brown JD; Shewale AR; Talbert JC
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1319-1329. PubMed ID: 27783556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study.
    Banerjee A; Benedetto V; Gichuru P; Burnell J; Antoniou S; Schilling RJ; Strain WD; Ryan R; Watkins C; Marshall T; Sutton CJ
    Heart; 2020 Jan; 106(2):119-126. PubMed ID: 31601729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
    Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Health Care Costs Based on Medication Adherence and Risk of Stroke and Bleeding in Patients Treated with Novel Anticoagulant Therapy.
    Deshpande CG; Kogut S; Willey C
    J Manag Care Spec Pharm; 2018 May; 24(5):430-439. PubMed ID: 29694285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England.
    Tan YY; Papez V; Chang WH; Mueller SH; Denaxas S; Lai AG
    Lancet Healthy Longev; 2022 Oct; 3(10):e674-e689. PubMed ID: 36150402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm.
    Shantsila E; Lip GY
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD003333. PubMed ID: 27629776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
    Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Rosenblatt L; Liu X; Hede S; Nadkarni A; Shank T
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1116-1127. PubMed ID: 30212268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.
    Lip GYH; Keshishian AV; Zhang Y; Kang A; Dhamane AD; Luo X; Klem C; Ferri M; Jiang J; Yuce H; Deitelzweig S
    JAMA Netw Open; 2021 Aug; 4(8):e2120064. PubMed ID: 34398204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non-valvular atrial fibrillation patients in England.
    Bakhai A; Petri H; Vahidnia F; Wolf C; Ding Y; Foskett N; Sculpher M
    J Eval Clin Pract; 2021 Feb; 27(1):119-133. PubMed ID: 32314853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.
    Lane DA; Raichand S; Moore D; Connock M; Fry-Smith A; Fitzmaurice DA;
    Health Technol Assess; 2013 Jul; 17(30):1-188. PubMed ID: 23880057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
    Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines.
    Bhatia K; Ladd LM; Carr KH; Di Napoli M; Saver JL; McCullough LD; Hosseini Farahabadi M; Alsbrook DL; Hinduja A; Ortiz Garcia JG; Sabbagh SY; Jafarli A; Divani AA
    Curr Neurol Neurosci Rep; 2023 May; 23(5):235-262. PubMed ID: 37037980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
    Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
    PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
    Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
    J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
    BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
    Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012169. PubMed ID: 28968483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
    J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.